Story perspectives

Trump Demands Lower Drug Prices Amid Rising Medicare Costs

8/20/2025

25 4

Summary

Story summary

President Trump demanded pharmaceutical companies lower drug prices to match the lowest in developed countries within 60 days, threatening consequences for non-compliance.
Eli Lilly and Novo Nordisk are offering direct-to-consumer sales, with Ozempic and Wegovy priced at $499 monthly for uninsured patients.
Analysts doubt direct sales will significantly reduce drug costs, as cash prices may remain unaffordable.
The Trump administration is exploring a pilot program to expand access to weight-loss drugs under Medicare.
Medicare Part D premiums may rise by up to $50 monthly due to increased drug spending and funding policy changes.

History

Historical Context

The Trump administration's 2018 American Patients First plan aimed to lower prescription drug prices for Medicare beneficiaries, with spending projected to reach $500 billion. This initiative echoes the 2003 Medicare Modernization Act, which expanded drug coverage but raised premiums. Ongoing debates about healthcare affordability in the U.S. highlight the complexities of pharmaceutical pricing strategies and their implications for patients.

1 of 2

Story summary

President Trump demanded pharmaceutical companies lower drug prices to match the lowest in developed countries within 60 days, threatening consequences for non-compliance.
Eli Lilly and Novo Nordisk are offering direct-to-consumer sales, with Ozempic and Wegovy priced at $499 monthly for uninsured patients.
Analysts doubt direct sales will significantly reduce drug costs, as cash prices may remain unaffordable.
The Trump administration is exploring a pilot program to expand access to weight-loss drugs under Medicare.
Medicare Part D premiums may rise by up to $50 monthly due to increased drug spending and funding policy changes.

1 / 2